Lakefront Biotherapeutics (LKFT)
LKFT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1421876/000110465926035163/0001104659-26-035163-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | LKFT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Belgium |
| IPO year | 2015 |
| SEC CIK | 0001421876 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Belgium |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.2B |
| Net income | $354.6M |
| Operating income | $326.1M |
| Net margin | 28.9% |
| Operating margin | 26.5% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $97.1M |
| Total assets | $3.8B |
| P/E (computed) | 6.5× |
| P/S (computed) | 1.9× |
Reported in EUR; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-26 |
| Cash and burn | $97.1M cash; operating cash flow -$71.1M a quarter. | Report 2025-12-31 |
| Shares outstanding | 65,897,071 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO Bedrijfsrevisoren - BDO Réviseurs d'Entreprises, Zaventem, Belgium | PCAOB Form AP 2026-04-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $1.2B | $354.6M | -$284.5M | $97.1M | No debt tags | $1.2B | 20-F 2026-03-26 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-05-08 |
| Latest annual report | 20-F | 2026-03-26 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 548 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.6% |
| 1 month | +17.0% |
| 3 months | +21.2% |
| Year to date | +3.9% |
| 1 year | +7.9% |
| From 52-week high | -1.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PBH | Prestige Consumer Healthcare Inc. | $48.00 | +3.92% | $2.3B |
| PHVS | Pharvaris N.V. | $32.44 | -2.76% | $2.3B |
| NAMS | NewAmsterdam Pharma Company N.V. | $19.46 | -3.38% | $2.3B |
| PRGO | Perrigo Company plc | $16.18 | -0.37% | $2.2B |
| RCUS | Arcus Biosciences Inc. | $16.86 | -3.27% | $2.4B |
| PVLA | Palvella Therapeutics Inc. | $144.60 | -5.17% | $2.1B |
| BHVN | Biohaven Ltd. Common Shares | $13.80 | -0.14% | $2.1B |
| IMNM | Immunome Inc. | $17.61 | -6.18% | $2.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier